CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 4,000 shares at $20.25 ($81,005)
- 4 Planned sale PRESIDENT AND CEO sold 3,700 shares at $20.06 ($74,228)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 1,500 shares at $20.03 ($30,045)
- 4 Planned sale PRESIDENT AND CEO sold 2,800 shares at $20.03 ($56,084)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 7,000 shares at an average $19.39 ($135,697)
- 4 Planned sale PRESIDENT AND CEO sold 6,000 shares at an average $19.29 ($115,723)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF OPERATING OFFICER sold 6,667 shares at $20.24 ($134,957)
- 144 Insider Sale of Securities
- 4 Planned sale CHIEF FINANCIAL OFFICER sold 3,250 shares at $20.63 ($67,039)
- 144 Insider Sale of Securities
- 4/A Planned sale PRESIDENT AND CEO sold 1,517 shares at $20.00 ($30,343)
- 4 Planned sale CHIEF SCIENTIFIC OFFICER sold 12,500 shares at an average $19.86 ($248,217)
- 4 Planned sale PRESIDENT AND CEO sold 10,983 shares at an average $20.02 ($219,906)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
Page 8 of 40 · 798 filings